If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-18. Numbers and descriptions here follow the published literature rather than marketing material.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
The branch extended to the Mezhdunarodnaya station in 2006; all work on the third station, Dorogomilovskaya (between Kiyevskaya and Delovoi Tsentr), has been postponed. The branch is planned for extension as far as the Savyolovskaya station, on the Serpukhovsko-Timiryazevskaya Line. On 5 March 2021, the company MTS announced the launch of the country's first pilot 5G network in Moscow.
CoA-glutathione + glutathione Thus, the two substrates of this enzyme are CoA and glutathione disulfide, whereas its two products are CoA-glutathione and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is CoA:glutathione-disulfide oxidoreductase. Other names in common use include glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione coenzyme A-glutathione transhydrogenase, glutathione:coenzyme A-glutathione transhydrogenase, coenzyme A:oxidized-glutathione oxidoreductase, and coenzyme A:glutathione-disulfide oxidoreductase. This enzyme participates in cysteine metabolism and glutathione metabolism.
==== Finasteride for androgenetic alopecia (hair loss in men) ==== The most common adverse effects of finasteride taken for hair loss are a decrease in sex drive, erectile dysfunction, and a decrease in the amount of semen. In addition, finasteride has been reported in case reports to cause sexual problems that persist after stopping the medication. A 2012 update to the FDA label noted reports of decreased sex drive, problems with ejaculation and difficulty achieving an erection which continued after stopping the medication. The update also referenced reports of testicular pain and "male infertility and/or poor quality of semen." In 2025, the European Medicines Agency confirmed that suicidal thoughts can occur as a side effect of the hair-loss treatment finasteride and similar dutasteride. The majority of these reports involved patients taking the 1 mg dosage, typically prescribed for androgenetic alopecia, a hormone-related form of hair loss. However, the agency noted that the precise frequency of this adverse effect could not be determined from the data available. In October 2024, the EMA had initiated a review of both finasteride and dutasteride due to concerns over potential links to suicidal ideation. While finasteride—marketed by Organon as Propecia—already includes warnings about possible psychiatric effects, the EMA stated that the evidence did not support a similar link for dutasteride, sold by GSK under the brand name Avodart.
=== Global and national expansion === Church's Chicken began its international expansion in the 1970s, in Canada, Mexico, Japan, and Puerto Rico. In the 1980s, it gained popularity in Indonesia when it opened under the trade name, "Texas Chicken". The first reason of changing the name to "Texas" is because the brand name "Church" was not popular in countries with majority non-Christian religions, such as Indonesia. Afterwards, locations in Malaysia, Taiwan, Singapore, and the Philippines were also opened under the trade name "Texas Chicken". In February 2008, Church's Chicken entered the UK market under the "Texas Chicken" name, claiming to have signed up 50 former Dixy Chicken franchisees. Only a small number of restaurants opened, with one in High Road Leytonstone, London, and another in Salford, Greater Manchester. They withdrew from the UK a few years later. In 2017, Church's Chicken announced a multi-year development deal with Goalz Restaurant Group, LLC to develop 20 Church's Chicken restaurants each year in Florida, Kentucky, Ohio, Colorado, North Carolina and South Carolina.
Charlemagne founded the Carolingian Empire in 800; it was divided in 843. The eastern successor kingdom of East Francia stretched from the Rhine in the west to the Elbe river in the east and from the North Sea to the Alps. Subsequently, the Kingdom of Germany and the Holy Roman Empire emerged from it. The Ottonian rulers (919–1024) consolidated several major duchies. In 996, Gregory V became the first German Pope, appointed by his cousin Otto III, whom he shortly after crowned Holy Roman Emperor. The Holy Roman Empire absorbed northern Italy and Burgundy under the Salian emperors (1024–1125), although the emperors lost power through the Investiture Controversy. Under the Hohenstaufen emperors (1138–1254), German princes encouraged German settlement to the south and east (Ostsiedlung). Members of the Hanseatic League, mostly north German towns, prospered in the expansion of trade. The population declined starting with the Great Famine in 1315, followed by the Black Death of 1348–1350. The Golden Bull issued in 1356 provided the constitutional structure of the Empire and codified the election of the emperor by seven prince-electors. Johannes Gutenberg introduced moveable-type printing to Europe, laying the basis for the democratisation of knowledge. Following Martin Luther's 1517 Protestant Reformation, bolstered by his standardised Bible translation, led to the 1555 Peace of Augsburg, which recognised Lutheranism under the principle of cuius regio, eius religio (ruler's faith dictates subjects' faith).
Sources: en.wikipedia.org
=== Angiogenesis for cardiovascular disease === Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. It is a potent, physiological process that underlies the natural manner in which our bodies respond to a diminution of blood supply to vital organs, namely neoangiogenesis: the production of new collateral vessels to overcome the ischemic insult. A large number of preclinical studies have been performed with protein-, gene- and cell-based therapies in animal models of cardiac ischemia, as well as models of peripheral artery disease. Reproducible and credible successes in these early animal studies led to high enthusiasm that this new therapeutic approach could be rapidly translated to a clinical benefit for millions of patients in the Western world with these disorders. A decade of clinical testing both gene- and protein-based therapies designed to stimulate angiogenesis in underperfused tissues and organs, however, has led from one disappointment to another. Although all of these preclinical readouts, which offered great promise for the transition of angiogenesis therapy from animals to humans, were in one fashion or another, incorporated into early stage clinical trials, the FDA has, to date (2007), insisted that the primary endpoint for approval of an angiogenic agent must be an improvement in exercise performance of treated patients.
=== Poisoning === Fomepizole, a drug that competitively inhibits alcohol dehydrogenase, can be used in the setting of acute methanol or ethylene glycol toxicity. This prevents the conversion of the methanol or ethylene glycol to its toxic metabolites (such as formic acid, formaldehyde, or glycolate). The same effect is also sometimes achieved with ethanol, again by competitive inhibition of ADH.
Somalia is a federal parliamentary representative democratic republic. The president of Somalia is the head of state and commander-in-chief of the Somali Armed Forces and selects the prime minister to lead as head of government. The Federal Parliament of Somalia is the national parliament of Somalia. The bicameral National Legislature consists of the House of the People (lower house) and the Senate (upper house), whose members are elected to serve four-year terms. The parliament elects the President, Speaker of Parliament and Deputy Speakers. It also has the authority to pass and veto laws. The Judiciary of Somalia is defined by the Provisional Constitution of the Federal Republic of Somalia. Adopted on 1 August 2012 by a National Constitutional Assembly in Mogadishu, the document was formulated by a committee of specialists chaired by attorney and Speaker of the Federal Parliament, Mohamed Osman Jawari. It provides the legal foundation for the existence of the Federal Republic and source of legal authority.
== Ownership and finance == Marks and Hazan initially supported GYG with their own money. In 2009, they sold a minority stake to Peter Ritchie, Guy Russo and Steve Jermyn, who had previously been involved with McDonald's Australia. Russo was subsequently appointed chairman of the board. The board also includes co-founder Robert Hazan, Tom Cowan of TDM Growth Partners, Rokt CEO Bruce Buchanan, and three former McDonalds executives. Investment firm TDM Growth Partners bought a stake in the company for $44 million in August 2018. In December 2020, the publicly listed Magellan Financial Group bought 10% of the company for $86.8 million. In May 2022, Magellan sold its 11.6% stake in the company to an entity owned by investment bank Barrenjoey Capital Partners for $140 million. Marks stated in 2019 that his goal was to list GYG on the Australian Securities Exchange. In 2020, he stated that he was also ambitious to expand the company's presence in the United States, citing Australia's "antiquated" labour laws, high rents, and expensive fresh produce. Marks resigned as CEO due to a health scare in May 2023, but he changed his mind and remained. Hilton Brett was appointed co-CEO in October 2023. GYG was listed on the Australian Securities Exchange on 20 June 2024.
Gajowniczek was transferred to Auschwitz on 8 October 1940. He and Kolbe met as inmates of Auschwitz in May 1941. When a camp prisoner appeared to have escaped, SS-Hauptsturmführer Karl Fritzsch ordered that ten other prisoners be executed by starvation in reprisal. Gajowniczek (prisoner number 5659) was one of those selected at roll call. When priest Maximilian Kolbe heard Gajowniczek cry out in agony over the fate of his family, he offered himself instead, for which he was later canonized. The switch was permitted. After two weeks, Kolbe (prisoner number 16670) and the three other survivors were put to death by an injection of carbolic acid. Gajowniczek was transferred from Auschwitz to Sachsenhausen concentration camp on 25 October 1944. He was liberated there by the Allies, after spending five years, five months, and nine days in concentration camps in total. He reunited with his wife Helena, six months later in Rawa Mazowiecka. She survived the war, but their sons were killed in a Soviet bombardment of Rawa Mazowiecka in January 1945 before his release.
Sources: en.wikipedia.org
== Prevalence == A number of studies have examined the prevalence of link rot within the World Wide Web, in academic literature that uses URLs to cite web content, and within digital libraries. In a 2023 study of the Million Dollar Homepage external links, it was found that 27% of the links resulted in a site loading with no redirects, 45% of links have been redirected, and 28% returned various error messages. A 2002 study suggested that link rot within digital libraries is considerably slower than on the web. The article found that about 3% of the objects were no longer accessible after one year, equating to a half-life of nearly 23 years. A 2003 study found that on the Web, about one link out of every 200 broke each week, suggesting a half-life of 138 weeks. This rate was largely confirmed by a 2016–2017 study of links in Yahoo! Directory (which had stopped updating in 2014 after 21 years of development) that found the half-life of the directory's links to be two years. A 2004 study showed that subsets of Web links (such as those targeting specific file types or those hosted by academic institutions) could have dramatically different half-lives. The URLs selected for publication appear to have greater longevity than the average URL. A 2015 study by Weblock analyzed more than 180,000 links from references in the full-text corpora of three major open access publishers and found a half-life of about 14 years, generally confirming a 2005 study that found that half of the URLs cited in D-Lib Magazine articles were active 10 years after publication.
Notch is a cell surface protein that functions as a receptor. Animals have a small set of genes that code for signaling proteins that interact specifically with Notch receptors and stimulate a response in cells that express Notch on their surface. Molecules that activate (or, in some cases, inhibit) receptors can be classified as hormones, neurotransmitters, cytokines, and growth factors, in general called receptor ligands. Ligand receptor interactions such as that of the Notch receptor interaction, are known to be the main interactions responsible for cell signaling mechanisms and communication. Notch acts as a receptor for ligands that are expressed on adjacent cells. While some receptors are cell-surface proteins, others are found inside cells. For example, estrogen is a hydrophobic molecule that can pass through the lipid bilayer of the membranes. As part of the endocrine system, intracellular estrogen receptors from a variety of cell types (such as ovary, prostate, lung, cardiovascular and central nervous systems) can be activated by estrogen produced in the ovaries. In the case of Notch-mediated signaling, the signal transduction mechanism can be relatively simple. As shown in Figure 2, the activation of Notch can cause the Notch protein to be altered by a protease. Part of the Notch protein is released from the cell surface membrane and takes part in gene regulation. Cell signaling research involves studying the spatial and temporal dynamics of both receptors and the components of signaling pathways that are activated by receptors in various cell types.
Adrien-Marie Legendre at PlanetMath. The True Face of Adrien-Marie Legendre (Portrait of Legendre) Biography at Fermat's Last Theorem Blog References for Adrien-Marie Legendre (in French) Eléments de géométrie (Paris : F. Didot, 1817) Elements of geometry and trigonometry, from the works of A. M. Legendre. Revised and adapted to the course of mathematical instruction in the United States, by Charles Davies. (New York: A. S. Barnes & co., 1858) : English translation of the above text Mémoires sur la méthode des moindres quarrés, et sur l'attraction des ellipsoïdes homogènes (1830) Théorie des nombres (Paris : Firmin-Didot, 1830) Traité des fonctions elliptiques et des intégrales eulériennes (Paris : Huzard-Courcier, 1825–1828) Nouvelles Méthodes pour la Détermination des Orbites des Comètes (Paris : Courcier, 1806) Essai sur la Théorie des Nombres (Paris : Duprat, 1798) Exercices de Calcul Intégral V.3 (Paris : Courcier, 1816) Correspondance mathématique avec Legendre in C. G. J. Jacobis gesammelte Werke (Berlin: 1852)
The four substrates of this enzyme are piceol (4-hydroxyacetophenone), reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are hydroquinone monoacetate, oxidised NADP+, and water. This enzyme is a flavoprotein of Baeyer-Villiger monooxygenase type, which uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is (4-hydroxyphenyl)ethan-1-one,NADPH:oxygen oxidoreductase (ester-forming). This enzyme is also called HAPMO. It participates in bisphenol a degradation.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.